Cornea

Immediate flushing of the eye can significantly reduce long-term damage after chemical exposure

After accounting for key factors like eye length, researchers found no meaningful differences in corneal biomechanics between primary open-angle and primary angle-closure glaucoma.

Examining the physiologic limits can help identify when its usage may be ineffective

A retrospective study from a UK tertiary centre reports satisfactory visual and topographic outcomes in patients monitored and treated by optometrists and nurse practitioners.

Understanding thyroid eye disease and its often-missed diagnosis.

The 3rd Winterthur Ophthalmology Symposium in Winterthur, Switzerland, on 12–13 March 2026 will feature plenary talks, hands-on workshops, satellite sessions, poster presentations, and a gala honoring the Otto Haab Medal.

Interventional therapies give patients faster relief and better outcomes

Real-world insights guide the way to tailored treatment.

Isocyclosporin is a dual inhibitor of transient receptor potential cation channel, mucolipin subfamily, member 2 (TRPML2), and calcineurin.

The novel therapeutic for keratoconus does not require corneal epithelium removal and is slated to launch commercially in early 2026.

Patients with higher exposure to nature and green spaces were significantly less likely to experience dry eye, investigators reported

Highlights from the 2025 Heidelberg Engineering International SPECTRALIS Symposium—And Beyond

Remaining questions about DED pertain to geographic considerations, prevalence measures for DED in children and the design of future studies to determine risk factors in patients under 40

Cabozantinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, has previously been associated with hepatic and dermatologic adverse effects

Research findings from the multicentre clinical study were presented at the European Society of Ophthalmology (SOE) meeting in Lisbon, Portugal

The investigational device, ETX-4143, was the focus of a study involving 31 patients with COSP in Australia

Ultraviolet light’s potential in ocular care extends beyond structural reinforcement to antimicrobial applications, especially for microbial keratitis

A five-step approach to personalise and simplify treatment, leading to higher efficacy

Ophthalmologists report that dry eye syndrome, myopia progression and other ocular pathologies have increased, especially among paediatric patient groups

Nordic Pharma plans to announce commercialisation details in the near future for the dry eye disease treatment

Aldeyra previously received a CRL for its initial New Drug Application for reproxalap in November 2023

AURN001 is Aurion Biotech's clinical-stage allogeneic cell therapy asset for corneal oedema secondary to corneal endothelial disease

The authors examined vascular and neural structures in the eye, assessing the foveal avascular zone and choroidal thickness

The Arise system utilises advanced algorithms to interpret corneal topography images, recommending lenses without requiring a fitting set